Cercare Medical Releases Neuroimaging Software Update

Cercare Medical has introduced new software designed to improve motion correction, configurable reporting, and tumor tissue analysis.

CERCARE MEDICAL NEUROSUITE Version 17 builds on a clear direction toward precision, automation, and smarter workflows, according to the company. “Version 17 reflects our ongoing focus on making advanced perfusion and diffusion imaging more actionable in real-world clinical workflows,” Cercare Medical Chief Commercial Officer Henrik Andersen said. “With better quality control, structured reporting options, and features like CMRO₂ thresholding and histogram-based tumor evaluation, CMN now delivers even more precise insights  that support confident, timely decisions at the point of care.”

Key Highlights of CMN Version 17: 

1. ROI Histogram Analysis for Tumor Evaluation 
A new histogram-based ROI analysis has been added to the ROI dashboard, providing metrics such as skewness, kurtosis, and mode – beyond mean and max. Literature indicates that this will result in enhanced glioma grading, improved differentiation between tumor progression and pseudoprogression, and greater interobserver reliability compared to hotspot-based analysis.

2. CMRO2 Thresholding for Infarct Core Detection
Recent research has found CT perfusion-derived CMRO₂ to be a promising parameter for estimating infarct core volume. Relative CMRO2 < 26% seems to be an optimal threshold, showing a significantly smaller volumetric bias and superior infarct core detection capability compared to the traditional rCBF < 30% method when referenced against DWI. Guided by this research, Cercare Medical now provides clinicians with a more precise tool for estimating the size of the irreversible core. This is crucial for guiding treatment decisions, particularly for time-sensitive interventions like endovascular therapy.

3. Automatic Removal of Low-Quality CT Perfusion Volumes 
Improved motion robustness by detecting and correcting 3D volumes with motion artifacts. Suboptimal volumes are automatically identified and replaced using adjacent frames, ensuring higher accuracy in time-sensitive cases like acute stroke. 

4. Configurable Summary Series for PACS 
Users can now configure summary series such as combining all derived perfusion maps into a single DICOM series – reducing clutter in PACS and enabling quicker review and decision-making. 

5. Structured Reporting with HL7 and DICOM SR Support
New configurable diagnostic reports in both HL7 and DICOM SR formats allow users to define which findings are included. This supports more consistent and standardized reporting for stroke and oncology workflows. 

6. Merging of Separate Diffusion Series
When B0 and B1000 images are sent as separate DICOM series, CMN can now merge them automatically – enabling diffusion processing even when split across different SeriesInstanceUIDs.

“We continue to innovate in close collaboration with clinical partners,” Cercare Medical Chief Technology Officer René Thomsen stated. “Version 17 includes several highly requested features—especially ROI histogram analysis for glioma grading and CMRO₂-based infarct core estimation—that push the boundaries of what’s possible in perfusion imaging.”

CMN Version 17 marks an important step in making advanced imaging more intelligent, flexible, and aligned with clinical needs, according to Cercare Medical. With its automation of quality checks, deeper tissue  insights, and streamlined reporting, the new version empowers users to make faster and more  confident decisions in both stroke and oncology.

Cercare Medical provides advanced perfusion imaging solutions. With fully automated, vendor-neutral software for computed tomography and magnetic resonance imaging perfusion post-processing, the company supports clinicians worldwide with tools that enhance diagnostics for stroke, oncology, Alzheimer’s disease, and other neurological conditions. Cercare’s proprietary biomarkers and automated pipelines enable better imaging maps, improving speed and confidence in clinical decision-making.